Aveanna Healthcare (AVAH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $505 million, up 7% year-over-year, with adjusted EBITDA of $45.6 million, a 27.3% increase, driven by growth in Private Duty Services and Medical Solutions, improved payer rates, and cost reduction initiatives.

• Net income for Q2 2024 was $13.9 million, down from $25.6 million in Q2 2023, mainly due to lower derivative gains and higher interest expense.

• Strategic focus on preferred payer partnerships and legislative advocacy led to double-digit rate improvements in Georgia and Massachusetts, and ongoing efforts in California tied to Proposition 35.

• Enhanced 2024 outlook projects full-year revenue above $1.985 billion and adjusted EBITDA above $158 million, reflecting strong execution and momentum.

• For the first six months of 2024, revenue rose 6.1% to $995.6 million, with net income of $2.7 million versus a net loss of $6.4 million in the prior year period.

Financial highlights

• Private Duty Services (PDS) revenue grew 8% to $408 million, with a 4.8% increase in care hours and a 3.2% rise in revenue per hour.

• Medical Solutions revenue increased 9.3% to $42.5 million, serving 94,000 unique patients, up 10.6%.

• Home Health and Hospice revenue declined 1.4% to $54.6 million, but gross margin improved by 5.2 points and episodic admissions rose 4.5% year-over-year.

• Consolidated gross margin was $158.3 million (31.3%), with PDS gross margin at 27.2% and Home Health and Hospice at 53.8%.

• Adjusted EBITDA for Q2 2024 was $45.6 million, up from $35.9 million in Q2 2023; for the first half, Adjusted EBITDA was $80.5 million, up from $64.3 million.

Outlook and guidance

• Full-year 2024 revenue expected to exceed $1.985 billion and adjusted EBITDA to surpass $158 million.

• Q3 anticipated to show seasonal softness in skilled business due to school closures and holidays, with a rebound expected in Q4.

• Preferred payer agreements in PDS targeted to reach 22-23 by year-end, supporting continued growth.

• Management expects continued growth in PDS and MS segments, supported by demand and reimbursement rate increases.

• The impact of the CMS Medicaid final rule is not expected to be material to results of operations.